VYNE Therapeutics (VYNE) Net Cash Flow (QoQ) (2017 - 2025)
VYNE Therapeutics (VYNE) Net Cash Flow (QoQ) (2017 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | VYNE Therapeutics | 1.19 Bn | 1.16 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -174.83% |
| Mar 31, 2025 | 129.64% |
| Dec 31, 2024 | 127.05% |
| Sep 30, 2024 | -226.58% |
| Jun 30, 2024 | 191.18% |
| Mar 31, 2024 | -176.16% |
| Dec 31, 2023 | 391.83% |
| Sep 30, 2023 | 45.73% |
| Jun 30, 2023 | -1,278.27% |
| Mar 31, 2023 | 84.90% |
| Dec 31, 2022 | 36.41% |
| Sep 30, 2022 | 12.66% |
| Jun 30, 2022 | -200.50% |
| Mar 31, 2022 | 181.99% |
| Dec 31, 2021 | 80.32% |
| Sep 30, 2021 | -232.70% |
| Jun 30, 2021 | -125.20% |
| Mar 31, 2021 | 495.97% |
| Dec 31, 2020 | 34.65% |
| Sep 30, 2020 | -160.60% |